Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Pak Fah Yeow International's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$103.2 Mil.
Pak Fah Yeow International's average Total Assets over the quarter that ended in Dec. 2025 was HK$840.3 Mil. Therefore, Pak Fah Yeow International's annualized ROA % for the quarter that ended in Dec. 2025 was 12.28%.
The historical rank and industry rank for Pak Fah Yeow International's ROA % or its related term are showing as below:
HKSE:00239'
s ROA % Range Over the Past 10 Years
Min: -4.49 Med: 6.33 Max: 12.34
Current: 10.86
During the past 13 years, Pak Fah Yeow International's highest ROA % was 12.34%. The lowest was -4.49%. And the median was 6.33%.
HKSE:00239's ROA % is ranked better than 85.22% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.625
vs HKSE:00239: 10.86
Pak Fah Yeow International (HKSE:00239) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pak Fah Yeow International's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pak Fah Yeow International ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pak Fah Yeow International's ROA % distribution charts can be found below:
* The bar in red indicates where Pak Fah Yeow International's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Pak Fah Yeow International (HKSE:00239) has a ROA % of 12.28% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pak Fah Yeow International and its competitors. This is 94% above median its historical median of 6.33. According to the industry distribution chart, Pak Fah Yeow International ranks #149 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Pak Fah Yeow International's ROA % too high?
Pak Fah Yeow International's current ROA % of 12.28% is 94% above median its 10-year median of 6.33. The Drug Manufacturers industry median ROA % is 2.63. Pak Fah Yeow International's value of 12.28% is 367.8% above this industry median. Based on the distribution chart, Pak Fah Yeow International ranks #149 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pak Fah Yeow International has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pak Fah Yeow International's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pak Fah Yeow International ranks #149 out of 1008 companies for ROA %. This places Pak Fah Yeow International in the top 15% of its industry — outperforming the majority of peers. The industry median ROA % is 2.63. Pak Fah Yeow International's value of 12.28% is 367.8% above this benchmark. While the company's 10-year median is 6.33 vs. the industry median of 2.63, Pak Fah Yeow International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.63, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pak Fah Yeow International's current ROA % of 12.28% is 367.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pak Fah Yeow International and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pak Fah Yeow International's current ROA % is 12.28%, which is 94% above median its own 10-year median of 6.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pak Fah Yeow International stock overvalued right now?
Based on GuruFocus' analysis, Pak Fah Yeow International (HKSE:00239) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.17, compared to a current price of HK$2.34 — trading 7.6% above its estimated fair value. The current ROA % is 12.28%, which is 94% above median its 10-year median of 6.33 and 367.8% above the Drug Manufacturers industry median of 2.63. Pak Fah Yeow International's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Pak Fah Yeow International (HKSE:00239), the current ROA % is 12.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pak Fah Yeow International (HKSE:00239) Overvalued in 2026?
Based on GuruFocus' analysis, Pak Fah Yeow International stock appears to be overvalued.
The current stock price of HK$2.34 is trading 7.6% above its estimated GF Value™ of HK$2.17.
GuruFocus considers Pak Fah Yeow International to be Fairly Valued.
Key valuation signals for HKSE:00239:
ROA %: 12.28% (94% above median its 10-year median of 6.33)
GF Value™: HK$2.17 vs. price of HK$2.34 (7.6% above fair value)
Industry Position: 367.8% above the Drug Manufacturers median (#149 of 1008)
No single metric tells the full story. See the HKSE:00239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pak Fah Yeow International Ltd, with its subsidiaries, is engaged in the manufacture and distribution of healthcare products, including Hoe Hin branded products. It also engages in real estate investment and treasury investment businesses. It has three business segments, namely healthcare, property investments, and treasury investments. The Company derives the majority of its revenues from the Healthcare segment.The Groups businesses cover Hong Kong, Macau, other regions in the Peoples Republic of China (the PRC or Chinese Mainland), Southeast Asia, North America and the United Kingdom.
80GF Score
Get the complete analysis for HKSE:00239
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00239 has been successfully added to your 
